All proceeds go to UCLA Jonsson Comprehensive Cancer Center for
Dr. Noah Federman's Research for Pediatric Cancers
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a incredibly comprehensive and & multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. Dr. Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
Pediatric Sarcomas, specifically Ewing sarcoma (ES), the tumor that Chords2Cure junior board member Mafalda von Alvensleben was diagnosed with in 2014, is a highly aggressive bone and soft tissue cancer that affects mainly children age 5 to 25. Only 3 in a million cases are reported each year, which makes it one of the rarest pediatric cancers. The pelvis is the most common area, followed by femur, tibia, humerus, and scapula. 5 year survival for a localized tumor is 70%, whereas it is 15%-20% when the tumor has spread at time of diagnosis. Higher dosages of the chemotherapy drugs in shorter intervals have improved the outcome over the past 30 years. It is critical to be treated at a hospital like UCLA that is experienced with ES.
Hepatoblastoma Is a rare malignant liver cancer occurring primarily in infants and children under the age of three. Chords2Cure junior board member Jaxon Blumenthal was diagnosed with this form of a rare cancer in 2013. Surgical removal of the tumor, adjuvant chemotherapy and liver transplantation have been used to treat hepatoblastoma. Primary liver transplantation provides, long term, disease free survival rate in the range of 80%. The presence of metastases is the strongest predictor of a poor prognosis. Hepatoblastoma is diagnosed in fewer than one million children.
OUR Mission is to keep pushing the course of research towards more revolutionary breakthroughs in pediatric cancer. All proceeds will go towards the funding of Dr. Federman's trial at the Sarcoma Program at the UCLA Jonsson Comprehensive Cancer Center.
We are supporting Dr. Federman's study investigating if a new drug called TK216 which helps in the treatment for recurring Ewing Sarcoma. The purpose of the phase I part of this study is to test the safety of TK216 in the treatment of advanced cancer. It will try to find the highest dose of TK216 that can be given without causing severe side effects. This study lay the groundwork for Dr. Federman's research that led to the FDA approval of a new drug ‘larotrectinib’, the first ‘tumor agnostic’ agent to be approved for unique advanced and metastatic pediatric and adult solid tumors that have a genomic TRK fusion. Further more C2C helped fund a new pediatric liver cancer research and clinical trial. The money we are raising helps fund a precision medicine initiative to discover novel targets and screen novel therapeutics in pediatric liver cancers to treat each patient individually.